Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$83.14 - $145.99 $297,225 - $521,914
-3,575 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $98,034 - $145,955
-983 Reduced 21.57%
3,575 $493,000
Q3 2021

Nov 15, 2021

SELL
$98.85 - $138.91 $41,022 - $57,647
-415 Reduced 8.35%
4,558 $633,000
Q2 2021

Aug 10, 2021

SELL
$65.78 - $105.02 $146,031 - $233,144
-2,220 Reduced 30.86%
4,973 $483,000
Q1 2021

May 17, 2021

BUY
$64.07 - $91.75 $12,557 - $17,983
196 Added 2.8%
7,193 $492,000
Q4 2020

Feb 12, 2021

BUY
$65.07 - $98.24 $151,352 - $228,506
2,326 Added 49.8%
6,997 $600,000
Q3 2020

Nov 13, 2020

SELL
$59.04 - $77.95 $38,198 - $50,433
-647 Reduced 12.17%
4,671 $304,000
Q2 2020

Aug 05, 2020

SELL
$29.01 - $74.23 $44,646 - $114,239
-1,539 Reduced 22.44%
5,318 $389,000
Q1 2020

May 14, 2020

SELL
$27.51 - $57.29 $27,592 - $57,461
-1,003 Reduced 12.76%
6,857 $233,000
Q4 2019

Feb 13, 2020

BUY
$40.86 - $57.65 $156,657 - $221,030
3,834 Added 95.23%
7,860 $428,000
Q3 2019

Nov 12, 2019

SELL
$37.38 - $49.47 $8,335 - $11,031
-223 Reduced 5.25%
4,026 $168,000
Q2 2019

Aug 13, 2019

SELL
$39.79 - $67.01 $125,736 - $211,751
-3,160 Reduced 42.65%
4,249 $186,000
Q1 2019

May 14, 2019

SELL
$34.52 - $53.29 $31,447 - $48,547
-911 Reduced 10.95%
7,409 $381,000
Q4 2018

Feb 05, 2019

SELL
$29.75 - $42.9 $98,323 - $141,784
-3,305 Reduced 28.43%
8,320 $308,000
Q3 2018

Nov 14, 2018

SELL
$32.79 - $43.0 $279,665 - $366,747
-8,529 Reduced 42.32%
11,625 $437,000
Q2 2018

Aug 10, 2018

BUY
$23.62 - $42.29 $476,037 - $852,312
20,154 New
20,154 $796,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.6B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.